All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Everest Medicines, Micot license MT1013 for China and Asia-Pacific, RMB 200M ($28.8M) upfront, RMB 1.04B ($149.8M) milestones
Licensing deal, rare disease, polypeptide, milestone payments - Read more

Ginkgo Bioworks, OpenAI collaborate on autonomous laboratory achieving 40% cost reduction in cell-free protein synthesis using GPT-5
Research collaboration, AI/ML, drug discovery, manufacturing, protein synthesis - Read more

Eisai, Henlius Biotech partner on anti-PD-1 serplulimab in Japan, $388M potential deal value
Licensing deal, oncology, antibody, milestone payments, royalties - Read more

THE GOOD
Clinical Trials

Bayer's asundexian (factor XIa inhibitor) shows 26% stroke recurrence reduction in Ph3 secondary stroke prevention trial
Small molecule, cardiovascular, factor XIa inhibitor, stroke, secondary prevention - Read more

Alvotech's AVT80 (vedolizumab) biosimilar meets pivotal pharmacokinetic study endpoints for inflammatory bowel diseases
Antibody, autoimmune, biosimilar, vedolizumab, ulcerative colitis, Crohn's disease - Read more

Orca Bio presents positive Ph2 data for Orca-T cell therapy in acute myeloid leukemia and myelodysplastic syndromes
Cell therapy, cancer, allogeneic T-cell immunotherapy, hematological malignancies, acute myeloid leukemia, graft-versus-host disease - Read more

Aicuris presents positive Ph3 data for pritelivir targeting helicase-primase complex in refractory herpes simplex virus
Small molecule, infectious disease, antiviral, herpes simplex virus, immunocompromised patients, helicase-primase inhibitor - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Astellas beats Q3 expectations as Vyloy cancer drug sales surge 426% despite pancreatic trial failure
Monoclonal antibody, oncology, financial, revenue impact - Read more

Bristol Myers Squibb beats full-year revenue expectations at $48.2B despite Eliquis and Cobenfy sales disappointing analysts
Small molecule, cardiovascular, neurological, financial, revenue impact - Read more

THE GOOD
Fundraises

Angitia Biopharmaceuticals raises $130M Series D, bone disease bispecific antibodies development
Bone disease, bispecific antibody, clinical-stage, osteoporosis - Read more

Veradermics raises $256M IPO, developing oral version of Rogaine molecule
Hair loss, small molecule, oral formulation, clinical-stage - Read more

Generate:Biomedicines lines up for IPO, AI-driven computational therapeutic candidate generation
AI/ML platform, drug discovery, antibody, asthma, oncology, platform technology - Read more

Eikon Therapeutics raises $381M IPO, oncology drug development including EIK1001
Oncology, clinical-stage, small molecule, immune modulator, PARP inhibitor - Read more

LB Pharmaceuticals raises $100M private placement for neuropsychiatric disease therapies
Neuropsychiatric, late-stage, clinical-stage, small molecule - Read more

Agomab Therapeutics raises $200M IPO, immunology and inflammatory disease therapies
Clinical-stage, immunology, inflammatory diseases, fibrotic diseases - Read more

SpyGlass Pharma raises $150M IPO, late-stage biopharmaceutical company development
Late-stage, biopharmaceutical - Read more

THE GOOD
Politics & Policy

TrumpRx government pharmaceutical platform launches Thursday with discounted drugs from Eli Lilly, Pfizer, Novo Nordisk, Amgen
Small molecule, cardiovascular, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Lawsuits

Novo Nordisk threatens legal action against Hims & Hers over compounded semaglutide pill launch
GLP-1 agonist, obesity, competitive, legal action - Read more

THE BAD
Strategic Plans

Quell Therapeutics halts QEL-001 CAR-Treg Ph1/2 liver transplant trial to prioritize preclinical autoimmune candidate
Cell therapy, autoimmune, CAR-T, rheumatoid arthritis, regulatory T cells, organ transplant rejection - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here